Previous Investments
Trillium Ventures is a private investment and investment advisory firm specializing in early stage medical technology companies. The founder and general partner, Thomas S. Porter, previously spent 18 years as a general partner for health care investments with EDF Ventures, an early stage technology venture capital firm which he co-founded. A representative listing of the companies in which Mr. Porter was an investor are summarized and linked below. Mr. Porter usually served as a co-founder and director of the investee company and often served as interim CEO and Chairman during the formative stages of the Company.
 |
GenVec, Inc. (Nasdaq: GNVC) Gene-based products that cause therapeutic proteins to be produced at the site of disease. Mr. Porter co-founded the company while at EDF and served as a director and Chairman of the Compensation Committee. Website: http://www.genvec.com Co-Investors: |
 |
HandyLab, Inc. DNA-based point-of-care testing devices for human disease and pharmacogenomics. Mr. Porter co-founded the company while at EDF and served as Chairman of the Board and Chairman of the Compensation Committee. Website: http://www.handylab.com Co-Investors: |
 |
IntraLase Corp. (Nasdaq: ILSE) Advanced laser, software, and disposable products for ophthalmic refractive surgery. Mr. Porter co-founded the company while at EDF and serves as a director, Chairman of the Audit Committee, and a member of the Compensation Committee. Website: http://www.intralase.com Co-Investors: |
 |
Selective Genetics, Inc. Site-specific gene therapeutics and DNA devices for tissue repair and regeneration. Mr. Porter co-founded the company and served as a director and Chairman of the Compensation Committee. Website: http://www.selectivegenetics.com Co-Investors: |
Representative Advisory Engagements
Mr. Porter has provided advisory services to a variety of early stage companies and related organizations. In addition to providing advice and coaching to the many companies founded by MBA students of the Ross School of the University of Michigan, where he serves as Executive-In-Residence, Porter has also served as a paid advisor for the following:
 |
Fund Evaluation Group, LLC Fund Evaluation Group, LLC (FEG) is an objective, full-service investment consulting firm, whose main purpose is to advise fiduciaries of endowments, foundations, corporations, retirement plans, and high net worth individuals in the development, enhancement, and evaluation of their investment programs. FEG’s clients manage nearly $30 billion in assets. The vast majority of the firm’s client base is in the not-for-profit sector and have been since it’s inception. Mr. Porter assisted FEG in developing the venture capital investing portion of its alternative asset investment program and assists FEG in the evaluation and selection of new venture capital fund partnerships. Website: http://www.feg.com/ |
 |
Nano Bio An early stage biopharmaceutical company developing products using its proprietary NanoStat™ antimicrobial nanoemulsion technology. Mr. Porter assists the Founder and CEO on strategic growth issues and the company's financing strategy. Website: http://www.nanobio.com |
 |
Van Andel Research Institute A world-class research institute dedicated to improving human health through the development of biotherapeutics utilizing diverse areas of investigations encompassing functional genomics, molecular and structural biology, cell biology, biochemistry, and proteomics. Mr. Porter helped found the Institute's Technology Advisory Board. Website: http://www.vai.org/vai/default.asp |